Skip to main content
. Author manuscript; available in PMC: 2023 Apr 19.
Published in final edited form as: Circulation. 2022 Feb 4;145(16):1218–1233. doi: 10.1161/CIRCULATIONAHA.121.056850

Figure 3. lncExACT1 inhibition induces physiological hypertrophy.

Figure 3.

A. QRT-PCR measurement of lncExACT1 in hearts from mice injected with LNA-GapmeR-Control (Con) or LNA-GapmeR-lncExACT1 (Gap) for 2 weeks. B. Heart weight (HW) relative to tibial length (TL). C. Relative wall thickness (RWT). D. Fractional shortening (FS). E. Lung weight (LW) relative to tibial length (TL). F. Left ventricular end diastolic internal dimension (LVIDd). G. QRT-PCR measurement of hypertrophy markers in the heart. H. Quantification of cardiomyocyte area from wheat germ agglutinin (WGA)-stained heart sections. I. Quantification of EdU, PCM1 double-positive cardiomyocytes in stained heart sections. J. Quantification of Ki67, PCM1 double-positive cardiomyocytes in stained heart sections. K. Quantification of pHH3, PCM1 double-positive cardiomyocytes in stained heart sections. *p<0.05, **p<0.01 by Student’s t test. Data shown as mean±SEM.